Bo-Zhen Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo-Zhen Chen has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Beibei Zhang
School of Chemical Sciences
9 shared publicationsChenchen Guo
School of Chemical Sciences University of Chinese Academy of Sciences Beijing PR China
7 shared publicationsHuiqun Wang
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 E Leigh Street, Richmond, VA 23298, USA
6 shared publicationsHua Dong
College of Chemistry and Chemical Engineering, Graduate University of Chinese Academy of Sciences, P. O. Box 4588, Beijing 100049, People's Republic of China
4 shared publicationsMingyang Jiao
School of Chemical Sciences University of Chinese Academy of Sciences Beijing PR China
4 shared publicationsBaerlike Wujieti
School of Chemical Sciences
3 shared publications
Latest Publications
- 5 April 2025
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 64 (15) , 7311-7324
Theoretical Studies on the Reduction of N2 to NH3/N2H4 Catalyzed by Chromium Complexes
Nitrogen fixation catalyzed by transition metal complexes provides an attractive alternative to the Haber-Bosch process and has received widespread attention. In this work, the reaction pathways of N2 to NH3/N2H4 catalyzed by dinuclear and mononuclear Cr-N2 complexes bearing cyclopentadienyl-phosphine ligands and mediated by LutH+ (as proton donors) and CrCp*2 (as electron donors) were investigated systematically using density functional theory calculations. The key step of the reactions was clarified as the first hydrogenation. The effect of different combinations of six proton sources (three pyridine acids and three anilino acids) and three electron sources (CrCp*2, CoCp*2, and CoCp2) on the reduction of N2 to NH3/N2H4 was also explored by calculating the critical step of the reactions. Based on the calculations, the dinuclear Cr-N2 complex is expected to be an effective catalyst for the reduction of N2 to NH3/N2H4 when using the combinations of CrCp*2 with each of the six proton sources and of CoCp*2 with anilino acids. Our work provides insights into understanding and optimizing Cr catalytic systems for efficient dinitrogen fixations.
- 5 April 2025
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 64 (15) , 7311-7324
Theoretical Studies on the Reduction of N2 to NH3/N2H4 Catalyzed by Chromium Complexes
Nitrogen fixation catalyzed by transition metal complexes provides an attractive alternative to the Haber-Bosch process and has received widespread attention. In this work, the reaction pathways of N2 to NH3/N2H4 catalyzed by dinuclear and mononuclear Cr-N2 complexes bearing cyclopentadienyl-phosphine ligands and mediated by LutH+ (as proton donors) and CrCp*2 (as electron donors) were investigated systematically using density functional theory calculations. The key step of the reactions was clarified as the first hydrogenation. The effect of different combinations of six proton sources (three pyridine acids and three anilino acids) and three electron sources (CrCp*2, CoCp*2, and CoCp2) on the reduction of N2 to NH3/N2H4 was also explored by calculating the critical step of the reactions. Based on the calculations, the dinuclear Cr-N2 complex is expected to be an effective catalyst for the reduction of N2 to NH3/N2H4 when using the combinations of CrCp*2 with each of the six proton sources and of CoCp*2 with anilino acids. Our work provides insights into understanding and optimizing Cr catalytic systems for efficient dinitrogen fixations.
- Open Access
Study on SHP2 Conformational Transition and Structural Characterization of Its High-Potency Allosteric Inhibitors by Molecular Dynamics Simulations Combined with Machine Learning
The src-homology 2 domain-containing phosphatase 2 (SHP2) is a human cytoplasmic protein tyrosine phosphatase that plays a crucial role in cellular signal transduction. Aberrant activation and mutations of SHP2 are associated with tumor growth and immune suppression, thus making it a potential target for cancer therapy. Initially, researchers sought to develop inhibitors targeting SHP2’s catalytic site (protein tyrosine phosphatase domain, PTP). Due to limitations such as conservativeness and poor membrane permeability, SHP2 was once considered a challenging drug target. Nevertheless, with the in-depth investigations into the conformational switch mechanism from SHP2’s inactive to active state and the emergence of various SHP2 allosteric inhibitors, new hope has been brought to this target. In this study, we investigated the interaction models of various allosteric inhibitors with SHP2 using molecular dynamics simulations. Meanwhile, we explored the free energy landscape of SHP2 activation using enhanced sampling technique (meta-dynamics simulations), which provides insights into its conformational changes and activation mechanism. Furthermore, to biophysically interpret high-dimensional simulation trajectories, we employed interpretable machine learning methods, specifically extreme gradient boosting (XGBoost) with Shapley additive explanations (SHAP), to comprehensively analyze the simulation data. This approach allowed us to identify and highlight key structural features driving SHP2 conformational dynamics and regulating the activity of the allosteric inhibitor. These studies not only enhance our understanding of SHP2’s conformational switch mechanism but also offer crucial insights for designing potent allosteric SHP2 inhibitors and addressing drug resistance issues.
Open AccessStudy on SHP2 Conformational Transition and Structural Characterization of Its High-Potency Allosteric Inhibitors by Molecular Dynamics Simulations Combined with Machine Learning
The src-homology 2 domain-containing phosphatase 2 (SHP2) is a human cytoplasmic protein tyrosine phosphatase that plays a crucial role in cellular signal transduction. Aberrant activation and mutations of SHP2 are associated with tumor growth and immune suppression, thus making it a potential target for cancer therapy. Initially, researchers sought to develop inhibitors targeting SHP2’s catalytic site (protein tyrosine phosphatase domain, PTP). Due to limitations such as conservativeness and poor membrane permeability, SHP2 was once considered a challenging drug target. Nevertheless, with the in-depth investigations into the conformational switch mechanism from SHP2’s inactive to active state and the emergence of various SHP2 allosteric inhibitors, new hope has been brought to this target. In this study, we investigated the interaction models of various allosteric inhibitors with SHP2 using molecular dynamics simulations. Meanwhile, we explored the free energy landscape of SHP2 activation using enhanced sampling technique (meta-dynamics simulations), which provides insights into its conformational changes and activation mechanism. Furthermore, to biophysically interpret high-dimensional simulation trajectories, we employed interpretable machine learning methods, specifically extreme gradient boosting (XGBoost) with Shapley additive explanations (SHAP), to comprehensively analyze the simulation data. This approach allowed us to identify and highlight key structural features driving SHP2 conformational dynamics and regulating the activity of the allosteric inhibitor. These studies not only enhance our understanding of SHP2’s conformational switch mechanism but also offer crucial insights for designing potent allosteric SHP2 inhibitors and addressing drug resistance issues.
- 14 February 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (5) , e6637
Design of new visible light Pt photocatalyst based on the TDDFT study of properties of transition metal complexes
Visible light photocatalysis has been paid a lot of attention because of its green and lower energy consuming. To trigger a reaction via energy transfer, a potential visible light photocatalyst not only has absorption under visible light but also needs a high triplet excitation energy. In this scene, the density functional theory B3LYP methods were used to investigate the properties of transition metal complex photocatalysts and design new potential visible light photocatalysts. The calculation result shows that the studied Ir complexes have a relatively high ET values (energy gap between the triplet excited state and ground state). The introduction of electron‐donating groups to Ir complexes causes a slight redshift in the absorption spectrum. Moreover, the electronic structure and atomic radius of the central metal atom have a great influence on the properties of those complexes of “fac‐M(ppy)3” (transition metal complexes with facial structure and three ppy ligands, M = Pt, Ni, Rh, Ru, Fe). Based on the study of transition metal complexes, new visible light Pt complex photocatalysts that have both good absorption under visible light and high ET value have been designed here. The designed new Pt complexes are expected to be potential candidates as visible light photocatalysts.
- 14 February 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (5) , e6637
Design of new visible light Pt photocatalyst based on the TDDFT study of properties of transition metal complexes
Visible light photocatalysis has been paid a lot of attention because of its green and lower energy consuming. To trigger a reaction via energy transfer, a potential visible light photocatalyst not only has absorption under visible light but also needs a high triplet excitation energy. In this scene, the density functional theory B3LYP methods were used to investigate the properties of transition metal complex photocatalysts and design new potential visible light photocatalysts. The calculation result shows that the studied Ir complexes have a relatively high ET values (energy gap between the triplet excited state and ground state). The introduction of electron‐donating groups to Ir complexes causes a slight redshift in the absorption spectrum. Moreover, the electronic structure and atomic radius of the central metal atom have a great influence on the properties of those complexes of “fac‐M(ppy)3” (transition metal complexes with facial structure and three ppy ligands, M = Pt, Ni, Rh, Ru, Fe). Based on the study of transition metal complexes, new visible light Pt complex photocatalysts that have both good absorption under visible light and high ET value have been designed here. The designed new Pt complexes are expected to be potential candidates as visible light photocatalysts.
- 9 February 2022
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 46 (9) , 4052-4056
[2+2] Cycloaddition or β-hydrogen elimination?—a DFT study of the reactions of propylene catalyzed by (PDI)Fe-metallacycle
The origin of the chemoselectivity of [2+2] cycloaddition reactions catalyzed by different (PDI)Fe-metallacycles is due to the different groups (N2 or CH3) coordinated with the Fe metal.
- 9 February 2022
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 46 (9) , 4052-4056
[2+2] Cycloaddition or β-hydrogen elimination?—a DFT study of the reactions of propylene catalyzed by (PDI)Fe-metallacycle
The origin of the chemoselectivity of [2+2] cycloaddition reactions catalyzed by different (PDI)Fe-metallacycles is due to the different groups (N2 or CH3) coordinated with the Fe metal.
- 9 March 2021
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 9 (11) , 4091-4101
Insights into the Regioselective Hydrocarboxylation of Styrenes with CO2 Controlled by the Ligand of Nickel Catalysts
- 9 March 2021
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 9 (11) , 4091-4101
Insights into the Regioselective Hydrocarboxylation of Styrenes with CO2 Controlled by the Ligand of Nickel Catalysts
- Open Access
- 1 January 2021
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 19, 2761-2774
Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation
GS-9669 is a non-nucleos(t)ide inhibitor (NNI) binding to the thumb site II of the Hepatitis C virus (HCV) NS5B polymerase and has advanced into phase II trials. To clarify the drug resistance mechanisms of GS-9669 caused by M423T/I/V, L419M, R422K, and I482L mutations of NS5B polymerase (GT1b) and the receptor-ligand interactions during the binding process, a series of molecular simulation methods including molecular dynamics (MD) simulations and adaptive steered molecular dynamics (ASMD) simulations were performed for the wild-type (WT) and six mutant NS5B/GS-9669 complexes. The calculated results indicate that the binding free energies of the mutant systems are less negative than that of the WT system, indicating that these mutations will indeed cause NS5B to produce different degrees of resistance to GS-9669. The mutation-induced drug resistances are mainly caused by the loss of binding affinities of Leu419 and Trp528 with GS-9669 or the formation of multiple solvent bridges. Moreover, the ASMD calculations show that GS-9669 binds to the thumb II sites of the seven NS5B polymerases in distinct pathways without any obvious energy barriers. Although the recognition methods and binding pathways are distinct, the binding processes of GS-9669 with the WT and mutant NS5B polymerases are basically controlled thermodynamically. This study clearly reveals the resistance mechanisms of GS-9669 caused by M423T/I/V, L419M, R422K, and I482L mutations of HCV NS5B polymerase and provides some valuable clues for further optimization and design of novel NS5B inhibitors.
- 1 January 2021
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 19, 2761-2774
Open AccessInsight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation
GS-9669 is a non-nucleos(t)ide inhibitor (NNI) binding to the thumb site II of the Hepatitis C virus (HCV) NS5B polymerase and has advanced into phase II trials. To clarify the drug resistance mechanisms of GS-9669 caused by M423T/I/V, L419M, R422K, and I482L mutations of NS5B polymerase (GT1b) and the receptor-ligand interactions during the binding process, a series of molecular simulation methods including molecular dynamics (MD) simulations and adaptive steered molecular dynamics (ASMD) simulations were performed for the wild-type (WT) and six mutant NS5B/GS-9669 complexes. The calculated results indicate that the binding free energies of the mutant systems are less negative than that of the WT system, indicating that these mutations will indeed cause NS5B to produce different degrees of resistance to GS-9669. The mutation-induced drug resistances are mainly caused by the loss of binding affinities of Leu419 and Trp528 with GS-9669 or the formation of multiple solvent bridges. Moreover, the ASMD calculations show that GS-9669 binds to the thumb II sites of the seven NS5B polymerases in distinct pathways without any obvious energy barriers. Although the recognition methods and binding pathways are distinct, the binding processes of GS-9669 with the WT and mutant NS5B polymerases are basically controlled thermodynamically. This study clearly reveals the resistance mechanisms of GS-9669 caused by M423T/I/V, L419M, R422K, and I482L mutations of HCV NS5B polymerase and provides some valuable clues for further optimization and design of novel NS5B inhibitors.